Document Detail

MedLine Citation:
PMID:  20065633     Owner:  NLM     Status:  MEDLINE    
Roche is co-developing tocilizumab (Actemra, RoActemra), a humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody, with Chugai Pharmaceutical. Tocilizumab is marketed in Japan for Castleman disease and several types of arthritis. The product is approved in the European Union for treatment of moderate-to-severe rheumatoid arthritis, and is currently undergoing review by the US Food and Drug Administration for this condition. Tocilizumab has also been studied for potential use in the treatment of other IL-6 related disorders including Crohn disease.
Adith Venkiteshwaran
Related Documents :
7051253 - Anatomic separation of the suprapatellar pouch spares its involvement by rheumatoid syn...
24570533 - Tetralogy of fallot with pheochromocytoma: an unusual therapeutic challenge.
8505183 - Risk indicators for inflammatory bowel disease.
Publication Detail:
Type:  Journal Article; Review     Date:  2009-09-10
Journal Detail:
Title:  mAbs     Volume:  1     ISSN:  1942-0870     ISO Abbreviation:  MAbs     Publication Date:    2009 Sep-Oct
Date Detail:
Created Date:  2010-01-12     Completed Date:  2010-04-05     Revised Date:  2013-05-31    
Medline Journal Info:
Nlm Unique ID:  101479829     Medline TA:  MAbs     Country:  United States    
Other Details:
Languages:  eng     Pagination:  432-8     Citation Subset:  IM    
Rensselaer Polytechnic Institute, Troy, NY, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal* / administration & dosage,  adverse effects,  immunology,  therapeutic use
Antibodies, Monoclonal, Humanized
Arthritis, Rheumatoid / drug therapy*
Clinical Trials as Topic
Crohn Disease / drug therapy*
Drug Administration Schedule
European Union
Giant Lymph Node Hyperplasia / drug therapy*
Receptors, Interleukin-6 / immunology*
Treatment Outcome
United States
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Receptors, Interleukin-6; 0/tocilizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Motavizumab.
Next Document:  Denosumab.